Increasing Number of Mergers and Acquisitions is Propelling South & Central America Overactive Bladder Treatment Market Growth
Through mergers and acquisitions (M&A), companies can gain a competitive edge by entering new markets and acquiring new technologies. The ongoing mergers and acquisitions in the overactive bladder treatment market are creating growth opportunities for various companies. In July 2021, Uro Medical strengthened its urology portfolio with the acquisition of Micron Medical, which offers wirelessly powered, injectable, microtechnology neurostimulators focused on treating overactive bladder. These neurostimulators, which can be easily incorporated into patients’ daily lives, offer a convenient, safe, minimally invasive, and cost-effective urological treatment option. In February 2021, Axonics Modulation Technologies, Inc.—a medical technology company—acquired Contura Ltd. and its proprietary product, Bulkamid, which is a urethral bulking agent for women with stress urinary incontinence (SUI). Axonics produces and markets novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction. The acquisition of Contura Ltd. provides an opportunity to expand its SNM business across the world and serve the large, highly underpenetrated SUI market. The company plans to offer urogynecologists and urologists a complete suite of clinically differentiated incontinence solutions to treat their patients. Thus, increasing number of mergers and acquisitions is propelling South & Central America overactive bladder treatment market growth
South & Central America Overactive Bladder Treatment Market Overview
The South & Central America overactive bladder treatment market is segmented into Brazil, Argentina, and the Rest of South & Central America. Brazil is expected to account for the largest share of the market in the region, and it is projected to register the highest CAGR during the forecast period. The market growth is attributed to the growing geriatric population and rising prevalence of chronic disorders. The region is witnessing the high prevalence of obesity, unhealthy lifestyle patterns, and other risks, which are contributing to overactive bladder syndrome. As a result, the awareness of overactive bladder treatment has increased across the region, which is influencing the market growth in the region.
South & Central America Overactive Bladder Treatment Market Segmentation
The South & Central America overactive bladder treatment market is segmented on the basis of pharmacotherapy, disease type, and country.
Based on pharmacotherapy, the South & Central America overactive bladder treatment market is segmented into anticholinergics, mirabegron, botox, neurostimulation, and intravesical instillation. The mirabegron segment registered the largest share of the market in 2022.
Based on disease type, the South & Central America overactive bladder treatment market is bifurcated into idiopathic overactive bladder and neurogenic bladder. The idiopathic overactive bladder segment held a larger share of the market in 2022.
Based on country, the South & Central America overactive bladder treatment market is segmented into Brazil, Argentina, and the Rest of South & Central America. Brazil dominated the market in 2022.
AbbVie Inc; Astellas Pharma Inc; Endo Pharmaceuticals Inc.; Hisamitsu Pharmaceutical Co., Inc.; Medtronic Plc; Pfizer Inc; and Teva Pharmaceutical Industries Ltd are the leading companies operating in the South & Central America overactive bladder treatment market.
| Report Attribute | Details |
|---|---|
| Market size in 2022 | US$ 472.49 Million |
| Market Size by 2028 | US$ 543.53 Million |
| CAGR (2022 - 2028) | 2.4% |
| Historical Data | 2020-2021 |
| Forecast period | 2023-2028 |
| Segments Covered |
By Pharmacotherapy
|
|
Regions and Countries Covered
|
|
| South and Central America | Brazil, Argentina, Rest of South and Central America |
| Market leaders and key company profiles |
|
The South & Central America Overactive Bladder Treatment Market is valued at US$ 472.49 Million in 2022, it is projected to reach US$ 543.53 Million by 2028.
As per our report South & Central America Overactive Bladder Treatment Market, the market size is valued at US$ 472.49 Million in 2022, projecting it to reach US$ 543.53 Million by 2028. This translates to a CAGR of approximately 2.4% during the forecast period.
The South & Central America Overactive Bladder Treatment Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the South & Central America Overactive Bladder Treatment Market report:
The South & Central America Overactive Bladder Treatment Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The South & Central America Overactive Bladder Treatment Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the South & Central America Overactive Bladder Treatment Market value chain can benefit from the information contained in a comprehensive market report.
Please tell us your area of interest
(Market Segments/ Regions and Countries/ Companies)
E 1803, Panchshil Towers,
Wagholi, Haveli,
Pune - 412207,
Maharashtra, India
US:+1 646 791 7070
sales@businessmarketinsights.com
Get Free Sample For South & Central America Overactive Bladder Treatment Market
